Equities analysts forecast that Sientra Inc (NASDAQ:SIEN) will report earnings per share (EPS) of ($0.71) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Sientra’s earnings. The highest EPS estimate is ($0.60) and the lowest is ($0.89). Sientra posted earnings of ($0.73) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 2.7%. The firm is scheduled to announce its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Sientra will report full-year earnings of ($2.81) per share for the current fiscal year, with EPS estimates ranging from ($3.43) to ($2.17). For the next year, analysts anticipate that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.91) to ($1.29). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Sientra.
Sientra (NASDAQ:SIEN) last released its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.15). The business had revenue of $17.55 million for the quarter, compared to analyst estimates of $17.00 million. Sientra had a negative return on equity of 119.59% and a negative net margin of 126.32%.
In other news, CFO Paul Sean Little bought 17,391 shares of the business’s stock in a transaction on Friday, June 7th. The stock was purchased at an average price of $5.75 per share, with a total value of $99,998.25. Following the transaction, the chief financial officer now directly owns 94,891 shares in the company, valued at $545,623.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Keith J. Sullivan bought 20,869 shares of the business’s stock in a transaction on Friday, June 7th. The shares were purchased at an average cost of $5.75 per share, with a total value of $119,996.75. Following the transaction, the director now owns 203,141 shares in the company, valued at $1,168,060.75. The disclosure for this purchase can be found here. 13.30% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. Formula Growth Ltd. lifted its position in Sientra by 9.1% during the 1st quarter. Formula Growth Ltd. now owns 120,000 shares of the medical instruments supplier’s stock worth $1,030,000 after acquiring an additional 10,000 shares during the last quarter. Citigroup Inc. increased its holdings in shares of Sientra by 101.7% during the 4th quarter. Citigroup Inc. now owns 19,000 shares of the medical instruments supplier’s stock worth $241,000 after purchasing an additional 9,579 shares during the period. Tarbox Family Office Inc. increased its holdings in shares of Sientra by 273.9% during the 1st quarter. Tarbox Family Office Inc. now owns 36,400 shares of the medical instruments supplier’s stock worth $312,000 after purchasing an additional 26,666 shares during the period. Great West Life Assurance Co. Can bought a new position in shares of Sientra during the 4th quarter worth about $64,000. Finally, Geode Capital Management LLC increased its holdings in shares of Sientra by 10.0% during the 4th quarter. Geode Capital Management LLC now owns 254,747 shares of the medical instruments supplier’s stock worth $3,237,000 after purchasing an additional 23,117 shares during the period. 86.05% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:SIEN traded down $0.15 during trading hours on Friday, reaching $5.69. 4,250 shares of the company traded hands, compared to its average volume of 1,380,551. The firm’s 50-day simple moving average is $6.49. The stock has a market capitalization of $165.68 million, a PE ratio of -1.74 and a beta of 0.29. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.16 and a current ratio of 1.52. Sientra has a 1-year low of $5.00 and a 1-year high of $26.79.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.